Vitamin D3 for Life

Live Enlightened

Article

Pathogenic VDR Mutations and Hereditary Vitamin D-Resistant Rickets: Evidence Synthesis

Previous related pageNew 3-Prime Regulatory Evidence and Why Its Direction Cannot Be GeneralisedNext related pageVDR Abundance, Regulation and Receptor Turnover: Evidence Synthesis
Study at a glance

What causes hereditary vitamin D-resistant rickets?

Rare inherited changes can severely damage the vitamin D receptor, the protein that allows cells to respond to active vitamin D. Poor calcium absorption can then lead to rickets, a disorder in which growing bones do not harden properly.

Can this happen even when active vitamin D levels are high?

Yes. The problem can be a faulty response to the hormone rather than a shortage of it. Different gene changes interfere with different receptor functions, so the effects are not identical in every affected person.

Do common differences in the vitamin D receptor gene mean the same thing?

No. The rare gene changes discussed here can cause major loss of receptor function. Common differences in the gene usually raise a different question about smaller differences that vary between cells and studies. They should not be treated as equivalent to this inherited disorder.

Read the full article below ↓

Hereditary vitamin D-resistant rickets (HVDRR) provides unusually direct human evidence for what happens when the vitamin D receptor itself loses function. Unlike a common-variant association, these rare disorders connect a pathogenic VDR genotype to a defined molecular defect and then to failure of receptor-mediated responses to 1,25-dihydroxyvitamin D. The evidence is powerful precisely because the mutations can break different parts of the receptor system in different ways.

The disease is receptor resistance, not simply vitamin D deficiency

Feldman and Malloy describe HVDRR as a severe early-onset disorder in which loss-of-function VDR mutations impair vitamin-D signalling. Typical biochemical consequences include hypocalcaemia, secondary hyperparathyroidism and hypophosphataemia with rickets, often despite very high endogenous 1,25-dihydroxyvitamin-D concentrations. That combination is mechanistically important: increasing hormone production cannot restore a receptor pathway that is unable to respond normally.

The dominant physiological defect is impaired intestinal VDR signalling and calcium absorption. Some patients can respond to very high concentrations of vitamin D metabolites when a mutant receptor retains partial function, but mutations that abolish DNA binding, RXR heterodimerisation, receptor production or other essential transcriptional steps can remain highly resistant. Treatment experience therefore reinforces the molecular point that ‘VDR mutation’ is not a single functional category.

Different domains produce different loss-of-function mechanisms

Mutations in the DNA-binding domain can preserve ligand binding while preventing the receptor from engaging DNA. Ligand-binding-domain mutations can instead reduce affinity for 1,25-dihydroxyvitamin D, disturb heterodimerisation with RXR, or impair coactivator recruitment. Nonsense, frameshift and splice-site mutations can truncate the protein or eliminate functional receptor expression. Each lesion interrupts a different step between hormone recognition and transcription.

This domain-level distinction is experimentally useful. A patient can therefore have severe hormone resistance because the receptor cannot bind ligand, because it cannot bind DNA, because it cannot assemble correctly with RXR, because it cannot recruit transcriptional machinery, or because sufficiently intact receptor protein is not produced. The same clinical label can arise from multiple molecular failures.

Five newly analysed patients linked sequence changes to receptor function

Malloy and colleagues analysed five previously unreported HVDRR patients from several countries. All had clinical and radiographic rickets and hypocalcaemia; four with available measurements had elevated circulating 1,25-dihydroxyvitamin D. The investigators sequenced VDR, recreated identified mutations in wild-type VDR cDNA and tested 1,25-dihydroxyvitamin-D3-mediated transactivation in COS-7 cells.

They identified four novel mutations together with two previously described variants. The novel changes included C60W in the DNA-binding domain, D144N and N276Y in the ligand-binding domain, and a two-base deletion affecting the exon-3 splice donor and producing premature termination. C60W, located in the second zinc finger, was completely inactive in transactivation assays and was interpreted as a DNA-binding failure. A frameshift mutation in another patient produced a severely truncated receptor; patient fibroblasts showed no specific radioligand binding and no 24-hydroxylase response to hormone.

The growing mutation catalogue maps receptor architecture onto human disease

At the time of the Malloy patient report, the authors summarised 50 unique VDR mutations, including deletions, splice-site mutations, nonsense changes, an insertion/duplication and numerous missense mutations distributed across the DNA: and ligand-binding domains. Feldman and Malloy’s synthesis similarly shows how this heterogeneous catalogue can be organised by receptor function rather than by variant name alone.

That organisation is more informative than simply counting mutations. Changes at ligand-contact residues such as Arg274 or His305 can lower hormone affinity. DNA-binding-domain mutations can leave ligand binding intact yet abolish DNA response. Other ligand-binding-domain mutations interfere with RXR or coactivators. The human disease therefore functions as a set of natural perturbation experiments across the VDR signalling chain.

Alopecia is informative but belongs to a distinct mechanistic question

Many, but not all, people with HVDRR develop alopecia. The mutation-class pattern is biologically important because it helps separate classical ligand-dependent endocrine signalling from an additional receptor function in hair follicles. However, this page does not use alopecia to redefine the HVDRR phenotype or imply that hair loss is inevitable. The dedicated VDR-Related Alopecia and Unliganded Hair-Follicle Biology synthesis addresses that distinct reader function.

What rare pathogenic mutations can, and cannot, tell us

The causal strength of HVDRR evidence is high for severe receptor dysfunction: pathogenic mutations with demonstrated molecular defects can produce profound resistance to 1,25-dihydroxyvitamin D and the associated mineral phenotype. But the external validity is narrow. These are rare, usually biallelic, high-impact mutations studied in small patient populations; they do not provide effect sizes for common VDR polymorphisms, ordinary variation in receptor abundance, or common multifactorial disease.

That distinction is why the governed comparison with Vitamin D Receptor Polymorphisms matters: rare Mendelian loss of function and common population variation answer different genetic questions.

Primary evidence used in this synthesis

  • Mutations in the vitamin D receptor and hereditary vitamin D-resistant rickets · BoneKEy Rep. 2014;3:510. DOI: 10.1038/bonekey.2014.5.
  • Vitamin D Receptor Mutations in Patients with Hereditary 1,25-Dihydroxyvitamin D-Resistant Rickets · Mol Genet Metab. 2014. DOI: 10.1016/j.ymgme.2013.10.014.

Related reading

Original sources